{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:17:40Z","timestamp":1790705860580,"version":"4.1.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"DOI":"10.1097\/qai.0b013e3181609da8","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T15:35:29Z","timestamp":1236267329000},"page":"441-448","source":"Crossref","is-referenced-by-count":45,"title":["Ethnicity, Race, and Gender"],"prefix":"10.1097","volume":"47","author":[{"given":"Ellen M","family":"Tedaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Absalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avis J","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith C","family":"Shlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"van den Berg-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210131","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.","volume":"281","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"R2-5-20210131","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"R3-5-20210131","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00126334-200312010-00004","article-title":"Grade 4 events are as important as AIDS events in the era of HAART.","volume":"34","author":"Reisler","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-5-20210131","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/aid.2005.21.743","article-title":"Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient\/physician choice in patients with hepatitis C co-infection.","volume":"21","author":"Mocroft","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R5-5-20210131","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1086\/422141","article-title":"Leport C, et al, for the Antiprotease Cohort (APROCO) Study Group. Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.","volume":"39","author":"Duval","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R6-5-20210131","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(03)14229-8","article-title":"Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.","volume":"362","author":"Chene","year":"2003","journal-title":"Lancet"},{"key":"R7-5-20210131","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1468-1293.2005.00290.x","article-title":"for the Groupe dEpidemiologie Clinique du SIDA en Aquitaine (GECSA). Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.","volume":"6","author":"Bonnet","year":"2005","journal-title":"HIV Med"},{"key":"R8-5-20210131","first-page":"451","article-title":"Costagliola D, et al, for the Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.","volume":"368","author":"May","year":"2002","journal-title":"Lancet"},{"key":"R9-5-20210131","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"R10-5-20210131","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/497610","article-title":"Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and\/or nelfinavir: an Adult AIDS Clinical Trials Group Study.","volume":"192","author":"Haas","year":"2005","journal-title":"J Infect Dis"},{"key":"R11-5-20210131","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"R13-5-20210131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics.","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R14-5-20210131","first-page":"55","article-title":"Sex differences in adverse reactions to antiretroviral drugs.","volume":"11","author":"Ofotokun","year":"2003","journal-title":"Top HIV Med"},{"key":"R15-5-20210131","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/sti.79.4.340","article-title":"Lactic acidosis in HIV infected patients: a systematic review of published cases.","volume":"79","author":"Arenas-Pinto","year":"2003","journal-title":"Sex Transm Infect"},{"key":"R16-5-20210131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1310\/VHBA-X9FE-YRQR-YVBK","article-title":"Racial differences in serum lipids in HIV+ women treated with protease inhibitor regimens.","volume":"5","author":"Bausserman","year":"2004","journal-title":"HIV Clin Trials"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/aid.2006.22.321","article-title":"Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.","volume":"22","author":"Bonjoch","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R19-5-20210131","first-page":"6","article-title":"FDA issues warning about d4T and ddI during pregnancy.","volume":"12","year":"2001","journal-title":"Treatmentupdate"},{"key":"R20-5-20210131","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.amjhyper.2004.06.001","article-title":"Racial\/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA).","volume":"17","author":"Kramer","year":"2004","journal-title":"Am J Hypertens"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.CIR.0000158136.76824.04","article-title":"State of disparities in cardiovascular health in the United States.","volume":"111","author":"Mensah","year":"2005","journal-title":"Circulation"},{"key":"R22-5-20210131","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"R23-5-20210131","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00126334-200008010-00003","article-title":"Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team.","volume":"24","author":"Currier","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-5-20210131","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa030264","article-title":"AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.","volume":"349","author":"Robbins","year":"2003","journal-title":"N Engl J Med"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1468-1293.2006.00346.x","article-title":"Thompson MA, et al, for the ESS40002 Study Team. A prospective, 96-week study of the impact of Trizivir, Combivir\/nelfinavir, and lamivudine\/stavudine\/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral naive patients: effects of sex and ethnicity.","volume":"7","author":"Kumar","year":"2006","journal-title":"HIV Med"},{"key":"R27-5-20210131","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(06)69074-0","article-title":"for the INITIO Trial International Co-ordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomized trial.","volume":"368","author":"Yeni","year":"2006","journal-title":"Lancet"},{"key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(06)69861-9","article-title":"A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomized trial.","volume":"368","author":"MacArthur","year":"2006","journal-title":"Lancet"},{"issue":"RR-17","key":"R29-5-20210131","first-page":"1","article-title":"1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.","volume":"41","author":"Castro","year":"1992","journal-title":"Morb Mort Wkly Rep"},{"key":"R33-5-20210131","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00002030-200405210-00002","article-title":"HIV associated nephropathy.","volume":"18","author":"Ross","year":"2000","journal-title":"AIDS"},{"issue":"Suppl 2","key":"R34-5-20210131","first-page":"S256","article-title":"HIV\/AIDS-dominant player in chronic kidney disease.","volume":"16","author":"Naicker","year":"2006","journal-title":"Ethn Dis"},{"key":"R35-5-20210131","first-page":"1993","article-title":"Weber R, et al, for the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"341","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"R36-5-20210131","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/00002030-200110190-00013","article-title":"Elevated blood pressure in subjects with lipodystrophy.","volume":"15","author":"Sattler","year":"2001","journal-title":"AIDS"},{"key":"R37-5-20210131","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.aids.0000171410.76607.f8","article-title":"Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.","volume":"19","author":"Seaberg","year":"2005","journal-title":"AIDS"},{"key":"R38-5-20210131","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.aids.0000222074.45372.00","article-title":"Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.","volume":"20","author":"Crane","year":"2006","journal-title":"AIDS"},{"key":"R39-5-20210131","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1468-1293.2005.00333.x","article-title":"Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients.","volume":"7","author":"Palacios","year":"2006","journal-title":"HIV Med"},{"key":"R40-5-20210131","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.285.11.1466","article-title":"Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study.","volume":"285","author":"Ickovics","year":"2001","journal-title":"JAMA"},{"key":"R41-5-20210131","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1525-1497.2003.20938.x","article-title":"Gifford AL, et al, for the HCSUS Consortium. Underdiagnosis of depression in HIV: who are we missing?","volume":"18","author":"Asch","year":"2003","journal-title":"J Gen Intern Med"},{"key":"R42-5-20210131","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/09540120500159284","article-title":"Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women.","volume":"18","author":"Cook","year":"2006","journal-title":"AIDS Care"},{"key":"R43-5-20210131","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1076\/jcen.25.5.654.14577","article-title":"Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS).","volume":"25","author":"Farinpour","year":"2003","journal-title":"J Clin Exp Neuropsychol"},{"key":"R44-5-20210131","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1086\/383031","article-title":"Anemia in HIV infection: clinical impact and evidence-based management strategies.","volume":"10","author":"Volberding","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R45-5-20210131","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.aids.0000162334.12815.5b","article-title":"Grinsztejn B, et al, for the 2NN Study Group. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.","volume":"19","author":"van Leth","year":"2005","journal-title":"AIDS"},{"key":"R47-5-20210131","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1353\/hpu.2005.0093","article-title":"The effect of socioeconomic status on the survival of people receiving care for HIV infection in the United States.","volume":"16","author":"Cunningham","year":"2005","journal-title":"J Health Care Poor Underserved"},{"key":"R48-5-20210131","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.mcna.2005.03.005","article-title":"HIV\/AIDS: a minority health issue.","volume":"89","author":"Cargill","year":"2005","journal-title":"Med Clin North Am"},{"key":"R49-5-20210131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1525-1497.2005.40109.x","article-title":"Racial and ethnic disparities in access to physicians with HIV-related expertise.","volume":"20","author":"Heslin","year":"2005","journal-title":"J Gen Intern Med"},{"key":"R50-5-20210131","first-page":"314","article-title":"The Institute of Medicine report Unequal Treatment: implications for academic health centers.","volume":"71","author":"Betancourt","year":"2004","journal-title":"Mt Sinai J Med"},{"key":"R51-5-20210131","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1086\/503903","article-title":"Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.","volume":"42","author":"Robertson","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R53-5-20210131","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group.","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R54-5-20210131","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00126334-200303010-00004","article-title":"HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.","volume":"32","author":"Puoti","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"R55-5-20210131","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1086\/375889","article-title":"Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in the body mass index in women in the HIV epidemiology research study cohort.","volume":"37","author":"Jones","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R56-5-20210131","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00042560-200001010-00011","article-title":"When obesity is desirable: a longitudinal study of the Miami HIV-1-Infected Drug Abusers (MIDAS) cohort.","volume":"23","author":"Shor-Posner","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R57-5-20210131","first-page":"557","article-title":"A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia.","volume":"39","author":"Amorosa","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R58-5-20210131","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM200103083441003","article-title":"Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.","volume":"344","author":"Sterling","year":"2001","journal-title":"N Engl J Med"},{"key":"R59-5-20210131","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.qai.0000234084.11291.d4","article-title":"Weidle PJ, et al, for the HOPS Investigators. Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients.","volume":"43","author":"Tedaldi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200804010-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:21:28Z","timestamp":1618039288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200804010-00005"}},"subtitle":["Differences in Serious Adverse Events Among Participants in an Antiretroviral Initiation Trial: Results of CPCRA 058 (FIRST Study)"],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181609da8","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}